**References**

[1] Gallardo E, Medina J, Sánchez JC, Viúdez A, Grande E, Porras I, Ramón Y Cajal T, Trigo J, Iglesias L, Capdevila J. SEOM clinical guideline thyroid cancer (2019). Clin Transl Oncol. 2020;22(2):223-35.

[2] Fagin JA, Wells SA Jr. Biologic and Clinical Perspectives on Thyroid Cancer. *N Engl J Med*. 2016;375(11):1054-67.

[3] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 2016;26(1):1-133.

[4] Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(12):1856-83.

[5] Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388(10061):2783-95.

[6] Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013:965212.

[7] Schneider DF, Chen H. New developments in the diagnosis and treatment of thyroid cancer. *CA Cancer J Clin*. 2013;63(6):374-94.

[8] Ain KB. Papillary thyroid carcinoma. Etiology, assessment, and therapy. Endocrinol Metab Clin North Am. 1995;24(4):711-60.

[9] Sadeghi H, Rafei M, Bahrami M, Haghdoost A, Shabani Y. Attributable risk fraction of four lifestyle risk factors of thyroid cancer: a meta-analysis. J Public Health (Oxf). 2018;40(2):e91-e98.

[10] Seib CD, Sosa JA. Evolving Understanding of the Epidemiology of Thyroid Cancer. Endocrinol Metab Clin North Am. 2019;48(1):23-35.

# [11] Dzieczkowski JF, Anderson KC. Transfusion Biology and Therapy. Harrison's Principles of Internal Medicine. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J (eds). 18th ed. New York. McGraw-Hill Education;2011(1);951-7.

[12] Franchini M, Liumbruno GM, Lippi G. The prognostic value of ABO blood group in cancer patients. *Blood Transfus*. 2016;14(5):434-40.

[13] Rummel SK, Ellsworth RE. The role of the histoblood ABO group in cancer. *Future Sci OA*. 2016;2(2):FSO107.

[14] Tam AA, Özdemir D, Fakı S, Bilginer MC, Ersoy R, Çakır B. ABO Blood Groups, Rh Factor, and Thyroid Cancer Risk: To 'B' or Not to 'B'. Endocr Res. 2020;45(2):137-46.

[15] Nix P, Nicolaides A, Coatesworth AP. Thyroid cancer review 2: management of differentiated thyroid cancers. Int J Clin Pract. 2005;59(12):1459-63.

[16] Mansour A, Mohammed MA, Anwar R, Elzafrany M, Omar NM. AB0 blood group and risk of malignancies in Egyptians. Int J Cancer Res 2014;10(2):81−95.

[17] Huang JY, Wang R, Gao YT, Yuan JM. ABO blood type and the risk of cancer - Findings from the Shanghai Cohort Study. *PLoS One*. 2017;12(9):e0184295.

[18] Kumar S, Modak PK, Ali SH, Barpanda SK, Gusain VS, Roy R. A retrospective study: ABO and Rh phenotype blood group distribution among blood donors in H.N.B. Base Hospital, Srinagar, Uttarakhand, India. J Family Med Prim Care. 2018;7(1):34-8.

[19] Ito N, Yokota M, Nagaike C, Morimura Y, Hatake K, Tanaka O, Matsunaga T. Simultaneous expression of keratan sulphate epitope (a sulphated poly-N-acetyllactosamine) and blood group ABH antigens in papillary carcinomas of the human thyroid gland. Histochem J. 1996;28(9):613-23.

[20] González-Cámpora R, García-Sanatana JA, Jordà i Heras MM, Salaverri CO, Vázquez-Ramírez FJ, Argueta-Manzano OE, Galera-Davidson H. Blood group antigens in differentiated thyroid neoplasms. Arch Pathol Lab Med. 1998;122(11):957-65.

[21] Yokota M, Ito N, Hirota T, Yane K, Tanaka O, Miyahara H, Matsunaga T. Histochemical differences of the lectin affinities of backbone polylactosamine structures carrying the ABO blood group antigens in papillary carcinoma and other types of thyroid neoplasm. Histochem J. 1995;27(2):139-47.

[22] Khoshsirat S, Peyvandi AA, Oroei M, Peyvandi H, Rezaeifard A. The Estimation of Thyroid Cancer Risk based on Type 2 Diabetes Mellitus and ABO Blood Group.Turk J Oncol 2019;35(1):64–9.